By Zheng Qi 2020-10-11

Malaria has remained one of humanity’s most persistent public health battles, and the question of why global eradication efforts are taking far longer than once predicted touches on every layer of biology, society, and public health infrastructure. At the core of this challenge is a parasite far more complex than many early 20th-century scientists ever anticipated, one that has evolved over tens of thousands of years to outmaneuver nearly every tool humans have deployed against it.

Unlike many vaccine-preventable diseases, malaria is not caused by a single, simple pathogen. The Plasmodium parasite that causes human malaria goes through a dizzying series of life stages: it first develops inside the gut of a female Anopheles mosquito, then travels through the human bloodstream to the liver, where it multiplies hidden from the immune system, before bursting back into red blood cells to trigger the cycles of fever, chills, and organ damage that define the disease. Some species, like Plasmodium vivax, can even lie dormant in the liver for months or years, reactivating long after a person has left a malaria-free area, creating hidden reservoirs of infection that are nearly impossible to track down. This biological complexity means no single intervention can fully break its transmission chain, even when communities use bed nets and medication consistently.

Compounding this biological hurdle is the disease’s deep, unshakable foothold in the world’s most vulnerable regions. More than 90% of global malaria cases are concentrated in sub-Saharan Africa, where vast, remote rural communities often sit at the edge of national health systems. Many of these populations live in areas with limited road access, no reliable electricity for refrigerating temperature-sensitive antimalarial drugs, and few trained health workers who can recognize early malaria symptoms before they progress to life-threatening severe illness. Mobile and migrant populations, who move across porous national borders for work or to escape conflict, often slip through the gaps of national surveillance programs, carrying low-level infections from one region to another and reigniting transmission in areas that once came close to elimination.

For decades, this neglected disease also faced a massive gap in research and development investment. For much of the late 20th century, malaria received only a tiny fraction of the global funding dedicated to diseases like HIV or tuberculosis, leaving critical gaps in our toolkit: the first widely deployed malaria vaccine was only approved in 2021, decades after vaccines for far less widespread diseases became routine. Even proven, existing tools often fail to reach the people who need them most. In many countries with fragile health systems, fewer than half of suspected malaria cases receive a diagnostic test before treatment, and underfunded local clinics often run out of life-saving artemisinin-based combination therapies at the peak of transmission season.

Even with the historic progress of the last 25 years — which has averted an estimated 2.3 billion malaria cases and 14 million deaths globally — these overlapping barriers have created a stubborn “last mile” that no single country has been able to cross quickly. Malaria eradication is not just a medical challenge: it requires sustained investment in health system strengthening, equitable access to tools for marginalized communities, and long-term global commitment to outpace a parasite that has spent millennia adapting to survive.

Edited by: Secretariat of the Asia-Pacific Network for Drug and Diagnostics Innovation
Produced by: Zheng Qi
Reviewed by: Zhang Haobing
Tel: 021-64377008-2510 Fax: 021-54108329
Address: 207 Ruijin 2nd Road, Huangpu District,Shanghai, P.R. China  Postcode: 200025